Advertisement
Screener

TherapeuticsMD, Inc. (TXMD) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

TherapeuticsMD, Inc. Financing Cash Flow

TherapeuticsMD, Inc. (TXMD) reported Financing Cash Flow of $3.15 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-27.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2025-03-27

  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-09-30 was $19.73M, a 38.01% decline year-over-year.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-06-30 was -$119.99M, a 28134.11% decline year-over-year.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for the quarter ending 2022-03-31 was -$5.00M, a 105.21% decline year-over-year.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for the quarter ending 2021-12-31 was $1.35M, a 95.73% decline year-over-year.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $3.15M.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $129.55M, a 60.49% increase from fiscal 2020.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for fiscal 2020 was $80.72M, a 57.25% decline from fiscal 2019.
  • TherapeuticsMD, Inc. net cash provided by (used in) financing activities for fiscal 2019 was $188.83M, a 16.00% increase from fiscal 2018.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2023-12-31$3.15M
10-K · filed 2025-03-27
2022-09-30$19.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$100.26M
derived: sum of 2 quarters · filed 2022-11-14
-$105.26M
10-Q · filed 2022-11-14
-$103.91M
derived: sum of 4 quarters · filed 2023-05-15
2022-06-30-$119.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
-$124.99M
10-Q · filed 2022-08-15
-$123.63M
derived: sum of 3 quarters · filed 2023-05-15
-$91.81M
derived: sum of 4 quarters · filed 2023-05-15
2022-03-31-$5.00M
10-Q · filed 2023-05-15
-$3.65M
derived: sum of 2 quarters · filed 2023-05-15
$28.18M
derived: sum of 3 quarters · filed 2023-05-15
$28.60M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31$1.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
$33.17M
derived: sum of 2 quarters · filed 2022-11-14
$33.60M
derived: sum of 3 quarters · filed 2022-11-14
$129.55M
10-K · filed 2022-03-23
2021-09-30$31.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$32.25M
derived: sum of 2 quarters · filed 2022-11-14
$128.20M
10-Q · filed 2022-11-14
$159.90M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$428.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15
$96.38M
10-Q · filed 2022-08-15
$128.08M
derived: sum of 3 quarters · filed 2022-08-15
$128.19M
derived: sum of 4 quarters · filed 2022-08-15
2021-03-31$95.95M
10-Q · filed 2022-05-16
$127.65M
derived: sum of 2 quarters · filed 2022-05-16
$127.76M
derived: sum of 3 quarters · filed 2022-05-16
$127.85M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$31.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
$31.81M
derived: sum of 2 quarters · filed 2022-03-23
$31.90M
derived: sum of 3 quarters · filed 2022-03-23
$80.72M
10-K · filed 2022-03-23
$80.72M
10-K · filed 2021-03-04
2020-09-30$106.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$200.00K
derived: sum of 2 quarters · filed 2021-11-12
$49.02M
10-Q · filed 2021-11-12
$49.02M
10-Q · filed 2020-11-09
$126.05M
derived: sum of 4 quarters · filed 2022-03-23
2020-06-30$94.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$48.92M
10-Q · filed 2021-08-04
$48.92M
10-Q · filed 2020-08-07
$125.95M
derived: sum of 3 quarters · filed 2022-03-23
$125.96M
derived: sum of 4 quarters · filed 2022-03-23
2020-03-31$48.82M
10-Q · filed 2021-05-06
$48.82M
10-Q · filed 2020-05-06
$125.85M
derived: sum of 2 quarters · filed 2022-03-23
$125.86M
derived: sum of 3 quarters · filed 2022-03-23
$237.55M
derived: sum of 4 quarters · filed 2022-03-23
2019-12-31$77.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23
$77.04M
derived: sum of 2 quarters · filed 2022-03-23
$188.73M
derived: sum of 3 quarters · filed 2022-03-23
$188.83M
10-K · filed 2022-03-23
$188.83M
10-K · filed 2020-02-24
2019-09-30$8.55K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
$111.70M
derived: sum of 2 quarters · filed 2020-11-09
$111.80M
10-Q · filed 2020-11-09
$112.23M
derived: sum of 4 quarters · filed 2021-03-04
2019-06-30$111.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07
$111.79M
10-Q · filed 2020-08-07
$112.22M
derived: sum of 3 quarters · filed 2021-03-04
$202.23M
derived: sum of 4 quarters · filed 2021-03-04
2019-03-31$100.11K
10-Q · filed 2020-05-06
$530.00K
derived: sum of 2 quarters · filed 2021-03-04
$90.55M
derived: sum of 3 quarters · filed 2021-03-04
$162.84M
derived: sum of 4 quarters · filed 2021-03-04
2018-12-31$429.89K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
$90.45M
derived: sum of 2 quarters · filed 2021-03-04
$162.74M
derived: sum of 3 quarters · filed 2021-03-04
$162.79M
10-K · filed 2021-03-04
2018-09-30$90.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$162.31M
derived: sum of 2 quarters · filed 2019-11-08
$162.36M
10-Q · filed 2019-11-08
$162.36M
derived: sum of 4 quarters · filed 2020-02-24
2018-06-30$72.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$72.34M
10-Q · filed 2019-08-09
$72.34M
derived: sum of 3 quarters · filed 2020-02-24
$140.91M
derived: sum of 4 quarters · filed 2020-02-24
2018-03-31$44.06K
10-Q · filed 2019-05-08
$44.06K
derived: sum of 2 quarters · filed 2020-02-24
$68.62M
derived: sum of 3 quarters · filed 2020-02-24
$69.98M
derived: sum of 4 quarters · filed 2020-02-24
2017-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24
$68.57M
derived: sum of 2 quarters · filed 2020-02-24
$69.93M
derived: sum of 3 quarters · filed 2020-02-24
$72.58M
10-K · filed 2020-02-24
2017-09-30$68.57M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$69.93M
derived: sum of 2 quarters · filed 2018-11-08
$72.58M
10-Q · filed 2018-11-08
$72.59M
derived: sum of 4 quarters · filed 2019-02-27
2017-06-30$1.36M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-30
$4.01M
10-Q · filed 2018-07-30
$4.02M
derived: sum of 3 quarters · filed 2019-02-27
$4.02M
derived: sum of 4 quarters · filed 2019-02-27
2017-03-31$2.65M
10-Q · filed 2018-05-07
$2.66M
derived: sum of 2 quarters · filed 2019-02-27
$2.66M
derived: sum of 3 quarters · filed 2019-02-27
$2.92M
derived: sum of 4 quarters · filed 2019-02-27
2016-12-31$10.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27
$11.02K
derived: sum of 2 quarters · filed 2019-02-27
$265.61K
derived: sum of 3 quarters · filed 2019-02-27
$137.23M
10-K · filed 2019-02-27
2016-09-30$1.02K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07
$255.61K
derived: sum of 2 quarters · filed 2017-11-07
$137.22M
10-Q · filed 2017-11-07
$137.86M
derived: sum of 4 quarters · filed 2018-02-23
2016-06-30$254.59K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03
$137.21M
10-Q · filed 2017-08-03
$137.86M
derived: sum of 3 quarters · filed 2018-02-23
$170.21M
derived: sum of 4 quarters · filed 2018-02-23
2016-03-31$136.96M
10-Q · filed 2017-05-03
$137.60M
derived: sum of 2 quarters · filed 2018-02-23
$169.96M
derived: sum of 3 quarters · filed 2018-02-23
$170.45M
derived: sum of 4 quarters · filed 2018-02-23
2015-12-31$642.75K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$33.00M
derived: sum of 2 quarters · filed 2018-02-23
$33.49M
derived: sum of 3 quarters · filed 2018-02-23
$92.97M
10-K · filed 2018-02-23
2015-09-30$32.36M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04
$32.85M
derived: sum of 2 quarters · filed 2016-11-04
$92.33M
10-Q · filed 2016-11-04
$92.36M
derived: sum of 4 quarters · filed 2017-02-28
2015-06-30$491.74K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
$59.98M
10-Q · filed 2016-08-05
$60.01M
derived: sum of 3 quarters · filed 2017-02-28
$102.90M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31$59.48M
10-Q · filed 2016-05-05
$59.51M
derived: sum of 2 quarters · filed 2017-02-28
$102.41M
derived: sum of 3 quarters · filed 2017-02-28
$102.74M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31$30.20K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
$42.92M
derived: sum of 2 quarters · filed 2017-02-28
$43.26M
derived: sum of 3 quarters · filed 2017-02-28
$43.30M
10-K · filed 2017-02-28
2014-09-30$42.89M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
$43.23M
derived: sum of 2 quarters · filed 2015-11-05
$43.27M
10-Q · filed 2015-11-05
$42.96M
derived: sum of 4 quarters · filed 2016-02-26
2014-06-30$334.23K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07
$374.29K
10-Q · filed 2015-08-07
$64.36K
derived: sum of 3 quarters · filed 2016-02-26
$30.54M
derived: sum of 4 quarters · filed 2016-02-26
2014-03-31$40.05K
10-Q · filed 2015-05-07
-$269.87K
derived: sum of 2 quarters · filed 2016-02-26
$30.20M
derived: sum of 3 quarters · filed 2016-02-26
$33.19M
derived: sum of 4 quarters · filed 2016-02-26
2013-12-31-$309.93K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26
$30.16M
derived: sum of 2 quarters · filed 2016-02-26
$33.15M
derived: sum of 3 quarters · filed 2016-02-26
$73.99M
10-K · filed 2016-02-26
2013-09-30$30.47M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07
$33.46M
derived: sum of 2 quarters · filed 2014-11-07
$74.30M
10-Q · filed 2014-11-07
$79.82M
derived: sum of 4 quarters · filed 2015-03-12
2013-06-30$2.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$43.83M
10-Q · filed 2014-08-07
$49.35M
derived: sum of 3 quarters · filed 2015-03-12
$51.30M
derived: sum of 4 quarters · filed 2015-03-12
2013-03-31$40.84M
10-Q · filed 2014-05-07
$46.36M
derived: sum of 2 quarters · filed 2015-03-12
$48.31M
derived: sum of 3 quarters · filed 2015-03-12
$52.71M
derived: sum of 4 quarters · filed 2015-03-12
2012-12-31$5.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$7.47M
derived: sum of 2 quarters · filed 2015-03-12
$11.87M
derived: sum of 3 quarters · filed 2015-03-12
$14.44M
10-K · filed 2015-03-12
2012-09-30$1.95M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05
$6.35M
derived: sum of 2 quarters · filed 2013-11-05
$8.92M
10-Q · filed 2013-11-05
$10.77M
derived: sum of 4 quarters · filed 2014-03-05
2012-06-30$4.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
$6.97M
10-Q · filed 2013-08-07
$8.82M
derived: sum of 3 quarters · filed 2014-03-05
$10.17M
derived: sum of 4 quarters · filed 2014-03-05
2012-03-31$2.57M
10-Q · filed 2013-05-10
$4.42M
derived: sum of 2 quarters · filed 2014-03-05
$5.77M
derived: sum of 3 quarters · filed 2014-03-05
$6.91M
derived: sum of 4 quarters · filed 2014-03-05
2011-12-31$1.86M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-05
$3.20M
derived: sum of 2 quarters · filed 2014-03-05
$4.34M
derived: sum of 3 quarters · filed 2014-03-05
$4.71M
10-K · filed 2014-03-05
2011-09-30$1.35M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-13
$2.48M
derived: sum of 2 quarters · filed 2012-11-13
$2.85M
10-Q · filed 2012-11-13
$155.00K
10-Q · filed 2011-11-07
2011-06-30$1.14M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
$1.50M
10-Q · filed 2012-08-09
$99.00K
10-Q · filed 2011-08-15
2011-03-31$367.24K
10-Q · filed 2012-05-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
Cocrystal Pharma, Inc. (COCP)United States$0.022B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86